Literature DB >> 16168841

Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer.

Lilie L Lin1, Perry W Grigsby, Matthew A Powell, David G Mutch.   

Abstract

PURPOSE: The aim of our study was to assess prognostic factors and overall survival after salvage radiotherapy for patients who had endometrial carcinoma and who experienced an isolated vaginal recurrence. METHODS AND MATERIALS: We reviewed the records of 50 patients treated at our institution between 1967 and 2003 for an isolated vaginal recurrence of endometrial carcinoma. Initial treatment for endometrial carcinoma was definitive surgery in 49 patients and definitive radiotherapy in 1 patient. The median time from initial diagnosis of endometrial carcinoma to recurrence was 25 months (range, 4-179 months). Three patients (6%) received external-beam radiotherapy alone, 8 patients (16%) received brachytherapy only, and 39 patients (78%) received combined external-beam radiation therapy and brachytherapy. Median dose of radiation to the recurrence was 60 Gy (range, 16-85 Gy). Overall survival was calculated by the Kaplan-Meier method. Endpoints were measured from the date of diagnosis of the vaginal recurrence. Median follow-up of survivors after recurrence was 53 months (range, 8-159 months).
RESULTS: The 5-year and 10-year disease-free and overall survivals were 68% and 55%, and 53% and 40%, respectively. On multivariate analysis, age (p = 0.0242), Grade 1 or 2 vs. Grade 3 tumor (p = 0.002), and size of recurrence (p < 0.001) were significant predictors of overall survival. All patients who had Grade 3 disease were dead by 3.6 years from the time of recurrence. Five patients experienced a Grade 3 or 4 complication.
CONCLUSIONS: Patients treated with radiotherapy for an isolated vaginal recurrence can be cured in over 50% the cases. Radiotherapy is well tolerated, with a low risk of complications. Factors predictive of overall survival include tumor grade, patient age at recurrence, and tumor size.

Entities:  

Mesh:

Year:  2005        PMID: 16168841     DOI: 10.1016/j.ijrobp.2005.02.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer.

Authors:  Sophia C Kamran; Matthias M Manuel; Paul Catalano; Linda Cho; Antonio L Damato; Larissa J Lee; Ehud J Schmidt; Akila N Viswanathan
Journal:  Brachytherapy       Date:  2017-08-17       Impact factor: 2.362

2.  Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.

Authors:  Melody J Xu; Christina Chu; Stephen Rubin; Lilie L Lin
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

3.  The utility and management of vaginal cytology after treatment for endometrial cancer.

Authors:  Akiva P Novetsky; Lindsay M Kuroki; L Stewart Massad; Andrea R Hagemann; Premal H Thaker; Matthew A Powell; David G Mutch; Israel Zighelboim
Journal:  Obstet Gynecol       Date:  2013-01       Impact factor: 7.661

4.  Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer.

Authors:  Shervin M Shirvani; Ann H Klopp; Anna Likhacheva; Anuja Jhingran; Pamela T Soliman; Karen H Lu; Patricia J Eifel
Journal:  Pract Radiat Oncol       Date:  2012-05-03

Review 5.  Brachytherapy for malignancies of the vagina in the 3D era.

Authors:  Scott M Glaser; Sushil Beriwal
Journal:  J Contemp Brachytherapy       Date:  2015-09-14

6.  Clinical outcomes of stage I endometrial carcinoma patients treated with surgery alone: Siriraj Hospital experiences.

Authors:  Suwanit Therasakvichya; Sompop Kuljarusnont; Janjira Petsuksiri; Pattama Chaopotong; Vuthinun Achariyapota; Pisutt Srichaikul; Atthapon Jaishuen
Journal:  J Gynecol Oncol       Date:  2016-05-16       Impact factor: 4.401

7.  Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma.

Authors:  Agnes Y Bahng; Christina Chu; Paul Wileyto; Stephen Rubin; Lilie L Lin
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

8.  Feasibility study and optimum loading pattern of a multi-ring inflatable intravaginal applicator.

Authors:  Hsiang-Chi Kuo; Keyur J Mehta; Ravindra Yaparpalvi; Linda Hong; Dinesh Mynampati; Wolfgang A Tomé; Shalom Kalnicki
Journal:  J Contemp Brachytherapy       Date:  2013-06-28

9.  Natural history of recurrences in endometrial carcinoma.

Authors:  Bengt Sorbe; Christian Juresta; Cecilia Ahlin
Journal:  Oncol Lett       Date:  2014-07-18       Impact factor: 2.967

10.  Institutional experience using interstitial brachytherapy for the treatment of primary and recurrent pelvic malignancies.

Authors:  Paul Aridgides; Benjamin Onderdonk; Mary Cunningham; Emily Daugherty; Lingyun Du; W Douglas Bunn; Rinki Agarwal; Seung Shin Hahn
Journal:  J Contemp Brachytherapy       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.